Study on Pregnancy Weight Gain and Outcomes Following Use of GLP-1 Medications Before Conception

What this Trial Is About

Researchers are studying pregnant women to understand how using glucagon-like peptide-1 receptor agonists GLP-1RAs for weight loss before pregnancy affects weight gain during pregnancy and pregnancy outcomes. This study compares women who used GLP-1RA medications before conceiving to those who did not use these medications. It aims to provide insights on how stopping GLP-1RA treatment before pregnancy influences maternal and newborn health. The study is observational and does not provide any treatment or intervention. About 400 pregnant women aged 18 to 45 years, who are at or before 20 weeks of pregnancy, will be enrolled. Participants will be divided into two groups based on whether they used GLP-1RA medications within three years before conception. Participants will complete questionnaires at several points during and after pregnancy, including early pregnancy, late pregnancy 32-36 weeks, 6-10 weeks postpartum, and 6 months postpartum. During the study, participants will provide information about their medication history, eating habits, and infant feeding practices through questionnaires. Clinical data about mother and baby will be collected from medical records. The main outcome measured is the amount of weight gained from the start of pregnancy to delivery. Researchers will also compare obstetrical outcomes and eating behaviors between groups. The study will last until April 2028, with multiple assessments over pregnancy and postpartum periods.

Gestational Response, Outcomes, and Weight After GLP-1 Use